Welcome to our dedicated page for IPERIONX SEC filings (Ticker: IPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IPERIONX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IPERIONX's regulatory disclosures and financial reporting.
IperionX Limited held a General Meeting on March 19, 2026, where shareholders approved four resolutions granting long-term equity incentives to founder executives Anastasios Arima (CEO) and Todd Hannigan (Executive Chair). All resolutions were carried by poll, with support ranging from about 82% to 95% of votes cast.
Shareholders approved up to 1,203,964 Options and 237,944 Performance Rights for Mr. Arima, and up to 992,170 Options and 196,086 Performance Rights for Mr. Hannigan. Option strike prices of A$18 and A$22 and a Performance Rights hurdle of a 30‑day VWAP of A$18 sit well above the A$6.76 share price on February 2, 2026, so value only arises if the share price increases substantially.
The company explains that executive pay is benchmarked to U.S. peers, reflecting its U.S.-based titanium technology and manufacturing focus. The awards have four‑year service requirements, five‑year terms, and, for Performance Rights, an additional one‑year lock‑up, aiming to link executive rewards to long-term shareholder value creation.
IPERIONX Ltd director Taylor Vaughn William has filed an initial ownership report showing direct holdings of 973,457 Ordinary Shares and 84,771 Restricted Stock Units. Footnotes state that 70,609 RSUs vest in December 2026 and 14,162 vest in December 2027, and that Ordinary Shares trade on the ASX.
IPERIONX Ltd director reports initial holdings in a Form 3 filing. Director R Tony Tripeny discloses beneficial ownership of 38,777 Ordinary Shares and 51,010 Restricted Stock Units. The Ordinary Shares trade on the Australian Stock Exchange. Of the RSUs, 36,848 vest in December 2026 and 14,162 vest in December 2027.
IPERIONX Ltd director Melissa Gowdy Waller filed an initial ownership report showing she holds 486,318 Ordinary Shares and 84,771 Restricted Stock Units of the company. According to the filing, 70,609 of these RSUs vest in December 2026 and 14,162 vest in December 2027.
IPERIONX Ltd Chief Financial Officer Marcela Rocha Castro filed an initial statement of beneficial ownership. She directly holds 380,841 IPX ordinary shares and 162,001 restricted stock units, with 79,666 scheduled to vest in December 2026 and 82,335 in December 2028. She also holds options over 216,672 IPX ordinary shares at a conversion price of A$5.00 per share, expiring in April 2029. IPX ordinary shares trade on the Australian Stock Exchange.
IPERIONX Ltd director Martin Lorraine M filed an initial ownership report showing a substantial stake in the company. The filing lists direct beneficial ownership of 1,177,138 Ordinary Shares and 90,216 Restricted Stock Units.
Of the RSUs, 76,054 are scheduled to vest in December 2026 and 14,162 in December 2027. IPX Ordinary Shares trade on the Australian Stock Exchange.
IPERIONX Ltd director Beverly Wyse has reported her initial ownership in the company. She holds 639,775 IPX Ordinary Shares directly, plus options over 106,093 IPX Ordinary Shares with an exercise price of 0.87 Australian Dollars per share that expire on May 12, 2026. She also holds 84,771 Restricted Stock Units, of which 70,609 vest in December 2026 and 14,162 vest in December 2027. IPX Ordinary Shares trade on the Australian Stock Exchange (ASX).
IperionX Limited filed a Form 6-K mainly to publish correspondence with the Australian Securities Exchange after a sharp share price move. ASX queried a change in IPX’s price from a high of $6.93 on 12 March 2026 to an intraday low of $4.58 on 16 March 2026. IperionX stated it is not aware of any information or reason that would explain the trading pattern, other than previously released disclosures. The company highlighted that its half year report was released last week and noted stakeholder questions about the funding mechanics of its U.S. Department of War grants. IperionX also confirmed it remains in compliance with ASX Listing Rules, including continuous disclosure obligations.
IperionX Limited reported a larger net loss of US$34.8 million for the six months ended December 31, 2025, compared with US$16.2 million a year earlier, as it ramped research, exploration and corporate spending to build its U.S. titanium platform. Cash and cash equivalents rose to US$65.8 million, supported by an October equity placement raising about US$46 million, lifting net assets to US$108.2 million. The company continued heavy investment in property, plant, equipment and intellectual property to scale titanium production in Virginia and advance the Titan critical minerals project in Tennessee. U.S. government support remains substantial, with US$59.8 million in DPA and IBAS awards by December 31, 2025 and a separate SBIR Phase III contract mechanism of up to US$99 million in potential task orders. After period end, the DoW obligated the final US$4.6 million under the IBAS award, transferred about 290 metric tons of titanium scrap at no cost, and IperionX received a US$0.3 million prototype order from American Rheinmetall, underscoring momentum toward commercialization.
IperionX Limited is offering 1,273,179 ordinary shares pursuant to a prospectus supplement dated February 23, 2026, with an offering price of $4.11 per share under a settlement agreement. The company will receive no proceeds from this issuance.
The shares are being sold directly by the company without underwriters and are expected to settle on or prior to February 24, 2026. Ordinary shares to be outstanding immediately after this offering are stated as 339,384,070 ordinary shares.